Hypoxia-reduced nitric oxide synthase activity is partially explained by higher arginase-2 activity and cellular redistribution in human umbilical vein endothelium

Placenta. 2011 Dec;32(12):932-40. doi: 10.1016/j.placenta.2011.09.003. Epub 2011 Oct 1.

Abstract

Hypoxia relates with altered placental vasodilation, and in isolated endothelial cells, it reduces activity of the endothelial nitric oxide synthase (eNOS) and l-arginine transport. It has been reported that arginase-2 expression, an alternative pathway for l-arginine metabolism, is increased in adult endothelial cells exposed to hypoxia as well as in pre-eclamptic placentae. We studied in human umbilical vein endothelial cells (HUVEC) whether hypoxia-reduced NO synthesis results from increased arginase-mediated l-arginine metabolism and changes in subcellular localization of eNOS and arginase-2. In HUVEC exposed (24 h) to 5% (normoxia) or 2% (hypoxia) oxygen, l-arginine transport kinetics, arginase activity (urea assay), and NO synthase (NOS) activity (l-citrulline assay) were determined. Arginase-1, arginase-2 and eNOS expression were determined by RT-PCR and Western blot. Subcellular localization of arginase-2 and eNOS were studied using confocal microscopy and indirect immunofluorescence. Experiments were done in absence or presence of S-(2-boronoethyl)-l-cysteine-HCl (BEC, arginase inhibitor) or N(G)-nitro-l-arginine methyl ester (l-NAME). Hypoxia-induced reduction in eNOS activity was associated with a reduction in eNOS phosphorylation at Serine-1177 and increased phosphorylation at Threonine-495. This was paralleled with an induction in arginase-2 expression and activity, and decreased l-arginine transport. In hypoxia the arginase inhibition, restored NO synthesis and l-arginine transport, without changes in the eNOS post-translational modification status. Hypoxia increased arginase-2/eNOS colocalization, and eNOS redistribution to the cell periphery. Altogether these data reinforce the thought that eNOS cell location, post-translational modification and substrate availability are important mechanisms regulating eNOS activity. If these mechanisms occur in pregnancy diseases where feto-placental oxygen levels are reduced remains to be clarified.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Arginase / antagonists & inhibitors
  • Arginase / biosynthesis*
  • Arginine / metabolism
  • Boronic Acids / pharmacology
  • Female
  • Fluorescent Antibody Technique, Indirect
  • Human Umbilical Vein Endothelial Cells / enzymology*
  • Humans
  • Hypoxia / metabolism*
  • Microscopy, Confocal
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide Synthase Type III / biosynthesis*
  • Phosphorylation
  • Pregnancy
  • Protein Processing, Post-Translational
  • Subcellular Fractions / enzymology

Substances

  • (2-boronoethyl)-cysteine
  • Boronic Acids
  • Arginine
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • ARG2 protein, human
  • Arginase
  • NG-Nitroarginine Methyl Ester